Antiplatelet Drugs
نویسندگان
چکیده
منابع مشابه
Antiplatelet drugs.
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is recommended as the first-line antiplatelet drug. Cl...
متن کاملPlatelets and new antiplatelet drugs
10.2217/14750708.2.3.465 © 2 part of latelets play an important, life-saving role in hemostasis and blood clotting at sites of ascular injury. However, unwanted platelet activation and arterial thrombus formation are mplicated in the onset of myocardial infarction, stroke and other cardiovascular diseases. ifferent mechanisms, such as vascular damage, the development of mural platelet thrombi s...
متن کاملAntiplatelet Drugs and Endothelial Function
Antiplatelets drugs, particularly cilostazol, an inhibitor of phosphodiesterase (PDE), are widely used for the treatment of ischemic stroke, transient ischemic attack, and peripheral arterial disease (PAD). The use of cilostazol reduces cardiovascular morbidity and mortality in patients with PAD as well as in patients with coronary artery disease (CAD) 1). Although the mechanisms underlying the...
متن کاملAntiplatelet drugs : is there a surgical risk?
Acetylsalicylic acid has long been the only nonsteroidal anti-inflammatory drug recommended for the treatment and prevention of thromboembolic diseases. More recently, new compounds have been used in patients with vascular diseases. However, these drugs are often associated with longer bleeding times and greater operative risk. In most surgical specialties, the question always arises as to whet...
متن کاملAntiplatelet drugs: which targets for which treatments?
The current standard care for acute coronary syndromes is dual antiplatelet therapy combining the COX1 inhibitor aspirin with a drug targeting the P2Y12 receptor, together with anticoagulation during and after early revascularization by percutaneous intervention. In very high-risk patients, glycoprotein (GP) IIb/IIIa antagonists may also be used. Secondary prevention of ischemic events requires...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chest
سال: 2012
ISSN: 0012-3692
DOI: 10.1378/chest.11-2293